CRIS Current Research Information System

TERRAGNA, CAROLINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.316
NA - Nord America 5.575
EU - Europa 3.969
AF - Africa 403
SA - Sud America 313
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 16.588
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.460
VN - Vietnam 1.892
CN - Cina 1.584
SG - Singapore 1.513
IT - Italia 1.022
GB - Regno Unito 693
DE - Germania 474
SE - Svezia 464
HK - Hong Kong 363
IN - India 269
FR - Francia 247
BR - Brasile 217
NL - Olanda 213
KR - Corea 191
RU - Federazione Russa 176
IE - Irlanda 138
CI - Costa d'Avorio 127
BD - Bangladesh 126
FI - Finlandia 116
JP - Giappone 91
UA - Ucraina 85
TG - Togo 78
ZA - Sudafrica 76
CH - Svizzera 64
CA - Canada 63
SC - Seychelles 55
AT - Austria 45
AR - Argentina 44
EE - Estonia 44
BG - Bulgaria 42
PH - Filippine 40
NG - Nigeria 37
TH - Thailandia 35
BE - Belgio 34
PL - Polonia 34
JO - Giordania 30
MX - Messico 30
ID - Indonesia 28
TR - Turchia 22
TW - Taiwan 22
IR - Iran 21
ES - Italia 20
IQ - Iraq 19
SA - Arabia Saudita 16
CO - Colombia 15
EC - Ecuador 15
GR - Grecia 10
CZ - Repubblica Ceca 8
RO - Romania 8
UZ - Uzbekistan 8
AU - Australia 7
CL - Cile 7
LT - Lituania 7
PK - Pakistan 6
GT - Guatemala 5
LB - Libano 5
TN - Tunisia 5
AL - Albania 4
CY - Cipro 4
DZ - Algeria 4
KE - Kenya 4
MA - Marocco 4
OM - Oman 4
RS - Serbia 4
SV - El Salvador 4
UY - Uruguay 4
EG - Egitto 3
HR - Croazia 3
HU - Ungheria 3
IL - Israele 3
JM - Giamaica 3
MY - Malesia 3
PS - Palestinian Territory 3
PT - Portogallo 3
PY - Paraguay 3
QA - Qatar 3
TT - Trinidad e Tobago 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
AZ - Azerbaigian 2
ET - Etiopia 2
EU - Europa 2
GH - Ghana 2
GY - Guiana 2
HN - Honduras 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PE - Perù 2
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
Totale 16.576
Salva come PNG Salva come JPEG
Città #
Singapore 1.040
Ashburn 713
Southend 584
Chandler 475
Ho Chi Minh City 470
Fairfield 379
Hefei 378
Hanoi 374
Hong Kong 347
San Jose 327
Bologna 237
Dallas 229
Ann Arbor 212
Beijing 200
Houston 182
Seoul 174
Seattle 162
Wilmington 162
Woodbridge 155
Dong Ket 151
Princeton 144
New York 142
Santa Clara 141
Dublin 138
Abidjan 127
Boardman 122
Cambridge 118
Los Angeles 96
Lauterbourg 94
Helsinki 89
Lomé 78
Tokyo 74
Milan 73
Bremen 66
Nanjing 62
Council Bluffs 56
Haiphong 56
Westminster 53
Frankfurt am Main 52
Munich 50
Padova 49
Bern 48
Da Nang 46
Hyderabad 46
Rome 44
São Paulo 43
Berlin 40
Sofia 40
Turin 39
Buffalo 37
Bengaluru 36
Guangzhou 35
Jacksonville 35
Jinan 35
Shenyang 34
Brussels 33
Redondo Beach 33
Abeokuta 31
Tianjin 31
Amman 30
Medford 30
Amsterdam 27
Fabriano 27
Redmond 26
Vienna 26
Biên Hòa 25
Changsha 24
Toronto 24
Warsaw 24
Saint Petersburg 23
Shanghai 23
Redwood City 22
Nanchang 21
San Diego 21
Zhengzhou 21
Falkenstein 20
Johannesburg 20
London 20
Quận Bình Thạnh 20
Salsomaggiore Terme 20
Chicago 19
Hebei 18
Ha Long 17
Jakarta 17
Nuremberg 17
Can Tho 16
Florence 16
Lappeenranta 16
Phoenix 16
Wuhan 16
Orem 15
Thái Nguyên 15
Washington 15
Atlanta 14
Falls Church 14
Montreal 14
Ninh Bình 14
Chengdu 13
Dearborn 13
Hangzhou 13
Totale 10.319
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 711
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 320
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 271
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 270
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 262
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 254
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 251
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 247
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 233
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 230
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 229
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 224
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 222
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 215
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 211
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 211
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 210
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 210
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 208
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 205
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 204
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 203
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 200
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 199
P-383 A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies 198
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 198
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 197
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 195
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 189
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 189
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 184
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 178
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 178
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 177
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 175
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 174
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 174
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 174
Cap dependent translation contributes to resistance of myeloma cells to bortezomib 173
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 171
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 170
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 168
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 166
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 166
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression 164
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 163
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 163
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 163
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 159
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 157
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 156
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 156
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 155
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 155
A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies 154
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 154
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 153
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 153
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 150
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 150
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia 148
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 147
Association between genotypes and response to the treatment in a subset of previously untreated chronic myeloid leukemia patients enrolled into the TOPS trial. 145
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 144
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 141
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 141
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 139
Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib 137
Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging 136
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 135
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation 133
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 132
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 131
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 128
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 128
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 126
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. 126
New drugs to overcome meccanisms of resistance in Ph+ leukemia: Bosutinib 126
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma 125
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 119
Unraveling the Role of Peroxisome Proliferator-Activated Receptor β/Δ (PPAR β/Δ) in Angiogenesis Associated with Multiple Myeloma 111
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche 111
COMPARISON BETWEEN NGS IGH/TCR AND RT-PCR BCR::ABL1 MINIMAL RESIDUAL DISEASE IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY ANALYSIS 111
Multiple myeloma: disease response assessment 111
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 109
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 109
Primary pulmonary T-cell lymphoproliferative disorders with a limited-stage, low proliferative index, and unusual clinical behavior: two cases of a rare occurrence 102
Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies 98
null 98
Proteasome inhibitors: Bortezomib in multiple myeloma 93
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 92
Gene expression profiling (gep) of myeloma (MM) cells to predict attainment near complete response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed MM 92
Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment? 88
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 87
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 84
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 79
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 77
Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma 68
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 64
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives 61
Totale 16.631
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.214
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.214
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021389 0 0 0 0 0 0 0 0 0 0 0 389
2021/20221.469 105 67 64 107 136 85 32 103 69 171 237 293
2022/20232.017 194 291 83 303 151 151 65 105 304 65 161 144
2023/2024770 58 83 64 61 59 174 46 111 19 32 30 33
2024/20252.505 155 260 199 198 257 110 197 90 42 248 184 565
2025/20267.004 584 1.221 584 508 613 311 575 247 1.318 497 318 228
Totale 16.906